Myocardial necrosis and severe biventricular dysfunction in the context of chronic ephedrine abuse

Authors

  • Efrén Martínez-Quintana Servicio de Cardiología. Complejo Hospitalario Universitario Insular-Materno Infantil. Las Palmas de Gran Canaria. España. Enviar correspondencia a: Efrén Martínez Quintana c/ Alcalde Ramírez Bethencourt 10 3-A CP: 35003 Las Palmas de Gran Canaria. España.
  • Fayna Rodríguez-González Unidad de Medicina Intensiva. Complejo Hospitalario Universitario Insular-Materno Infantil. Las Palmas de Gran Canaria. España.
  • Javiel Cuba-Herrera Servicio de Cardiología. Complejo Hospitalario Universitario Insular-Materno Infantil. Las Palmas de Gran Canaria. España.

DOI:

https://doi.org/10.20882/adicciones.211

Keywords:

Ephedrine, ephedra, necrosis, infarction, myocardial, addiction

Abstract

Ephedra is an amphetamine-like compound with a potent sympathomimetic effect. Ephedrine, its active component, is widely used for weight loss, to enhance athletic performance or as component of some drugs. Its cardiovascular effects include tachycardia, increased inotropy, arterial vasoconstriction and hypertension, and these are the effects for which it is used therapeutically. However, it can also cause adverse effects, such as neuropathy, myopathy, psychosis, addiction, stroke, insomnia, myocarditis, arrhythmias, myocardial infarction or sudden death. We present the case of a patient, with pre-existing psychiatric conditions, who developed congestive heart failure and pulmonary oedema in the context of severe biventricular dysfunction and myocardial necrosis secondary to longstanding ephedrine abuse. Secondary causes of dilated myocardiopathy such as alcohol abuse, autoimmunity, hemochromatosis, thyroid alterations, viral or bacterial myocarditis and coronary heart disease, were ruled out. Five years after total cessation of use of the drug containing ephedrine, the patient is symptom-free, with partial recovery of left ventricular ejection fraction.

References

Andraws R, Chawla P, Brown DL. Cardiovascular effects of ephedra alkaloids: a comprehensive review. Prog Cardiovasc Dis 2005; 47: 217-25.

Miller SC. Safety concerns regarding ephedrine-type alkaloidcontaining

dietary supplements. Milit Med 2004; 169: 87–93.

Maglione M, Miotto K, Iguchi M, Jungvig L, Morton SC, Shekelle PG. Psychiatric effects of ephedra use: an analysis of Food and Drug Administration reports of adverse events. Am J Psychiatry 2005; 162: 189-91.

Goldfrank LR, Hoffman RS. The cardiovascular effects of cocaine. Ann Emerg Med 1991; 20: 165-175.

Kranjec I, Cerne A, Noc M. Ephedrine-Induced Acute Myocardial Infarction in a Young Athlete: A Case of Thrombus Management. Angiology 2009; 60: 254-8

Cockings JG, Brown M. Ephedrine abuse causing acute myocardial infarction. Med J Aust 1997; 167: 199-200.

To LB, Sangster JF, Rampling D, Cammens I. Ephedrine-induced

cardiomyopathy. Med J Aust 1980; 2: 35-6.

Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 2003; 289: 1537-45.

Miller SC. Psychiatric effects of ephedra: addiction. Am J Psychiatry 2005; 162: 2198

Published

2010-03-01

Issue

Section

Originals